Labopharm's CEO James Howard-Tripp talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Feb. 20, 2001 The Wall Street Transcript has published an in-depth interview with James Howard-Tripp, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Labopharm (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :DDS (1) (Digital Data Storage) See DAT. (2) (Data Dictionary System) See QuickBuild and OpenDDS. (3) (Dataphone Digital S ), in which he talks at length about the company's future. The entire 3,000-word interview is available free online at http://www.twst.com/ceos.htm Howard-Tripp gives an overview of the company. "The company went public in the middle of 1996. That was the time at which a lot of companies were going public. In retrospect, it probably went public a little early, and needed a little more time to mature. It's taken from then to about the middle of last year for all the various pieces to come together that would constitute what we would look at as being a successful company." Howard-Tripp explains: "One platform technology is a cross-linked, high amylose amylose /am·y·lose/ (am´i-los) a linear, water-soluble glucan; the soluble constituent of starch, as opposed to amylopectin. am·y·lose n. 1. starch starch, white, odorless, tasteless, carbohydrate powder. It plays a vital role in the biochemistry of both plants and animals and has important commercial uses. . We're the dominant group in the world to work with a starch as a matrix system for controlled drug The United Kingdom Misuse of Drugs Act 1971 aimed to control the possession and supply of numerous listed drugs and drug-like substances. The act allowed and regulated the use of some Controlled Drugs (designated CD) by various classes of persons (e.g. release. Our system is also patent protected." Looking forward, Howard-Tripp states: "I think they should look at the next year as being absolutely critical for us. We believe we've got a series of relatively aggressive milestones. We believe that we can meet those milestones, and it should put us either at the point, or very close to the point, of having filed for regulatory approval and having approval on at least one of our products." This interview is part of a 49-page Global Healthcare Issue available at http://www.twst.com/info/info285.htm or by calling (212) 952-7433 The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors Long-term investor A person who makes investments for a period of at least five years in order to finance his or her long-term goals. for over 38 years. The Wall Street Transcript has launched a new free service where investors can ask Labopharm (or any public company) a question at http://www.qawire.com Serious investors may now receive free email alerts containing links to TWST articles whenever TWST publishes an interview on the companies they follow by using the new Alerts.com service available at http://www.twst.com/alerts.html. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call (800) 246-7673. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion